Axxcess Wealth Management LLC Boosts Stake in Sanofi (NASDAQ:SNY)

Axxcess Wealth Management LLC lifted its holdings in Sanofi (NASDAQ:SNY) by 75.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,153 shares of the company’s stock after purchasing an additional 3,500 shares during the quarter. Axxcess Wealth Management LLC’s holdings in Sanofi were worth $470,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently modified their holdings of the company. Manning & Napier Advisors LLC purchased a new stake in Sanofi during the second quarter valued at $13,725,000. Mount Yale Investment Advisors LLC increased its position in Sanofi by 44.3% during the first quarter. Mount Yale Investment Advisors LLC now owns 41,707 shares of the company’s stock valued at $2,027,000 after acquiring an additional 12,806 shares during the last quarter. GFS Advisors LLC increased its position in Sanofi by 1,017.9% during the third quarter. GFS Advisors LLC now owns 12,800 shares of the company’s stock valued at $738,000 after acquiring an additional 11,655 shares during the last quarter. Atria Investments Inc increased its position in Sanofi by 31.1% during the first quarter. Atria Investments Inc now owns 98,878 shares of the company’s stock valued at $4,805,000 after acquiring an additional 23,463 shares during the last quarter. Finally, Envestnet Portfolio Solutions Inc. increased its position in Sanofi by 15.2% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 116,917 shares of the company’s stock valued at $5,673,000 after acquiring an additional 15,439 shares during the last quarter. Hedge funds and other institutional investors own 10.04% of the company’s stock.

Analyst Ratings Changes

SNY has been the subject of several recent research reports. Argus boosted their price target on Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a report on Friday, July 26th. StockNews.com lowered Sanofi from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 7th. Finally, Citigroup raised Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Two research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $57.50.

Sanofi Stock Performance

NASDAQ SNY opened at $49.51 on Thursday. The firm has a market cap of $125.65 billion, a price-to-earnings ratio of 25.30, a price-to-earnings-growth ratio of 1.28 and a beta of 0.61. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. The business has a 50-day moving average price of $55.23 and a 200-day moving average price of $52.25. Sanofi has a twelve month low of $45.13 and a twelve month high of $58.97.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, topping analysts’ consensus estimates of $0.22 by $1.35. The firm had revenue of $13.44 billion during the quarter, compared to analyst estimates of $16.59 billion. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The business’s quarterly revenue was up 12.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.55 earnings per share. As a group, equities research analysts predict that Sanofi will post 4.27 EPS for the current fiscal year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.